Project Grant R01AI192982
Award Date 8/24/26
Completion Date 7/31/31
Dollars Obligated $847K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital Corporation, doing business as Boston Children's Hospital, $445,000 on February 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate novel immunoregulatory mechanisms that modulate myeloid trained immunity following transplantation. The research examines innate immune responses in transplant recipients, focusing on how monocytes expressing neuropilin 2 (NRP2) can...
- The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital Corporation (doing business as Boston Children's Hospital) $267,000 on July 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate regulatory B cell function in transplant alloimmunity. The project examines whether neuropilin-2 (NRP2)-expressing B cell subsets promote immunoregulation and suppress CD4+ T effector cell activation in the context of organ transplant...
- The National Institute of Allergy and Infectious Diseases awarded Brigham & Women's Hospital Inc. $726,885 on August 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a Project Grant (R01AI201728) to develop a novel cell-based immunotherapy using chimeric antigen receptor (CAR) regulatory T cells (Tregs) targeted against intercellular adhesion molecule (ICAM-1) to suppress ischemia-reperfusion injury and alloimmunity in transplant recipients. The...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $822,280 on August 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on intragraft alloreactive T cells in human solid organ transplantation, with the goal of controlling rejection after transplantation. The research dissects intragraft T cell alloimmunity using longitudinal surveillance biopsies from intestinal...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded $267,000 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research decoding gasdermin D (GSDMD) pore clustering as a regulatory checkpoint controlling pyroptosis, a lytic and inflammatory form...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts General Hospital $416,622 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 23, 2026. The award funds an R21 project grant investigating ex-vivo machine perfusion to promote tolerance induction in deceased donor kidney transplantation. The research team will explore normothermic machine perfusion strategies to preserve kidneys and reduce ischemia reperfusion injury (IRI), enabling...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts Institute of Technology $100,228 on November 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). MIT will conduct research examining the molecular basis of T cell allorecognition in graft-versus-host disease and graft-versus-leukemia. The research uses a repertoire-scale examination to determine the molecular mechanisms underlying T cell recognition of non-self major...
- The National Institute of Allergy and Infectious Diseases awarded Cincinnati Children's Hospital Medical Center $243,000 on May 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to model fibroblast-cholangiocyte interactions in chronic ductopenic rejection using primary human cholangiocyte organoids. Chronic ductopenic rejection is the most common immunologic cause of liver allograft loss in children. The research uses human liver tissue samples and...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $489,500 Project Grant to The Children's Hospital Corporation (Boston Children's Hospital) on July 9, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project, titled "Overcoming Obstacles in Structural Elucidation of B Cell Antigen Receptor Assembly and Lateral Interaction," will be conducted through June 30, 2027, in Massachusetts. The research...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $162,792 on August 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant R21AI202489) to develop and validate an antibody-mediated rejection (AMR)-on-a-chip platform that recapitulates key pathological features of AMR in kidney transplant rejection in vitro. The recipient will engineer a glomerulus-on-a-chip model using human induced pluripotent stem cell-derived renal...